source
- BioMarin drops BMN 401 after Phase 3 trial misses clinical endpoints, ending $270M Inozyme assetBioMarin announced it will stop development of BMN 401, an enzyme replacement therapy acquired in its $270 million purchase of Inozyme Pharma. The decision follows the Phase 3 ENERGY trial in pati…
- Denali Therapeutics' Avlayah generates $3.6M in Q1, beating forecastsDenali Therapeutics reported that its newly launched Hunter syndrome therapy Avlayah earned $3.6 million in revenue during the first quarter after its April market entry. Analysts had projected ro…